Chun A H, Erdman K, Zhang Y, Achari R, Cavanaugh J H
Pharmaceutical Products Division, Abbott Laboratories, Abbott Park, Illinois 60064-6118, USA.
Clin Ther. 2000 Feb;22(2):231-6. doi: 10.1016/S0149-2918(00)88481-7.
This study was designed to compare the bioavailability of lansoprazole when administered as an intact capsule and when the contents are admixed with various soft foods.
Patients sometimes cannot swallow or have difficulty swallowing intact capsules such as lansoprazole. To enable them to ingest the drug, the contents of the capsule can be admixed with small amounts of soft foods.
Twenty-four healthy adult volunteers participated in this single-dose, 4-period crossover study by ingesting the contents of a 30-mg lansoprazole capsule that had been emptied into either a tablespoon of yogurt (regimen A), Ensure pudding (regimen B), or cottage cheese (regimen C), or given as an intact capsule (regimen D) during the first study period. The regimen assignments were rotated at weekly intervals so that each subject received each regimen. Blood samples were obtained over the 12-hour period after administration of each regimen, and pharmacokinetic parameters were determined.
Of the 23 subjects who completed all 4 periods of the study, 18 were male and 5 were female. Their mean (+/- SD) age was 33.3+/-11.6 years, and their ages ranged from 19 to 52 years. No statistically significant differences between regimens were detected in mean maximum concentration, area under the curve (AUC) from time zero to the last measurable concentration, and AUC from time zero to infinity (AUC0-infinity) using analysis of variance. A statistically significant difference was detected in the time to maximum concentration between regimens C and D at 2.1 and 1.5 hours, respectively (P < or = 0.05). Bioavailability was assessed by the two 1-sided tests procedure using a 90% CI for the AUC0-infinity ratio of test-to-reference regimens. The 90% CIs were all within an acceptable equivalence range of 0.80 to 1.25.
These results indicate similar bioavailabilities between the regimen in which the lansoprazole capsule was emptied and administration of the intact capsule. However, they may have limitations in predicting the results in ill, elderly, or very young patients.
本研究旨在比较兰索拉唑以完整胶囊形式给药以及其内容物与各种软食混合后的生物利用度。
患者有时无法吞咽或难以吞咽完整的胶囊,如兰索拉唑胶囊。为使他们能够摄入药物,可将胶囊内容物与少量软食混合。
24名健康成年志愿者参与了这项单剂量、4期交叉研究,在第一个研究期间,他们摄入了一粒30毫克兰索拉唑胶囊的内容物,该胶囊内容物已被倒入一汤匙酸奶(方案A)、安素布丁(方案B)、农家干酪(方案C)中,或作为完整胶囊给药(方案D)。方案分配每周轮换一次,以便每个受试者接受每种方案。在每种方案给药后的12小时内采集血样,并测定药代动力学参数。
在完成研究所有4期的23名受试者中,18名男性,5名女性。他们的平均(±标准差)年龄为33.3±11.6岁,年龄范围为19至52岁。使用方差分析,各方案之间在平均最大浓度、从零时间到最后可测量浓度的曲线下面积(AUC)以及从零时间到无穷大的AUC(AUC0-无穷大)方面未检测到统计学显著差异。在方案C和D达到最大浓度的时间分别为2.1小时和1.5小时,检测到统计学显著差异(P≤0.05)。使用90%置信区间的测试与参比方案的AUC0-无穷大比值的双侧单侧检验程序评估生物利用度。90%置信区间均在可接受的等效范围0.80至1.25内。
这些结果表明,兰索拉唑胶囊内容物给药方案与完整胶囊给药的生物利用度相似。然而,它们在预测患病、老年或非常年轻患者的结果时可能存在局限性。